Mind Medicine (MindMed) Inc. MNMD
Set alert
As of Apr 2, 3:59 PM ET
- YTD
- +54.52%
- 1 year
- +219.78%
- Open
- 20.15
- Prev close
- 20.69
- Mkt cap
- 1.56B
- Vol
- 298.41K
- Avg vol
- 2.19M
- EPS
- -2.04
- P/E
- -10.56
- Div yield
- 0.00%
More statistics
- Low
- 19.95
- High
- 21.10
- Beta
- 2.62
- Inst. own
- 41.65%
- Dividend
- 0.00
- Earnings
- May 7, 2026
Key statistics
- Market cap
- 1.56B
- Enterprise value
- 4.26B
- Trailing P/E
- -10.56
- PEG ratio
- 0.14
- Price / sales
- 0.00
- Price / book
- 4.38
- Beta
- 2.62
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Total cash
- 0
- Total debt
- 0
- Return on equity
- -85.23%
Analyst view
- Strong buy7
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
May 7, 2026
Expected May 7, 2026. Consensus EPS estimate -0.5038.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 7, 2026 | Mar 31, 2026 | -0.478 | — | — | — |
| Mar 5, 2026 | Dec 31, 2025 | -0.48 | -0.51 | -0.03 | -6.25% |
| Nov 6, 2025 | Sep 30, 2025 | -0.52 | -0.78 | -0.26 | -50.00% |
| Jul 31, 2025 | Jun 30, 2025 | -0.38 | -0.50 | -0.12 | -31.58% |
| May 8, 2025 | Mar 31, 2025 | -0.36 | -0.35 | +0.01 | +2.78% |
| Mar 6, 2025 | Dec 31, 2024 | -0.33 | -0.41 | -0.08 | -24.24% |
About Mind Medicine (MindMed) Inc.
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering new treatments for various brain health conditions, encompassing psychiatric disorders, addiction, pain, and neurological ailments. Among its key pipeline assets is MM-120, currently undergoing Phase 2 clinical trials. This candidate is being investigated for its potential in addressing generalized anxiety disorder, attention deficit hyperactivity disorder (ADHD), and chronic pain. Furthermore, MM-110, an a3ß4 nicotinic cholinergic receptor antagonist, has successfully completed Phase 1 studies for managing opioid withdrawal. The company's portfolio also includes MM-402, an R-enantiomer of 3,4-methylenedioxymethamphetamine, aimed at treating the core symptoms associated with autism spectrum disorder. Its corporate headquarters are situated in Vancouver, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- CA
- Employees
- 74
- Website
- definiumtx.com
News
- FDA Accelerates Action on Treatments for Serious Mental Illness Following Executive Order
- 'Bipartisan Senators File Bill To Support Psychedelics Research And Treatment For Veterans' - Marijuana Moment
- Short Interest in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Grows By 19.4%
- Mind Medicine (MindMed) Inc. (MNMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Mind Medicine (MindMed) (NASDAQ:MNMD) CEO Robert Barrow Sells 25,791 Shares of Stock
- MNMD Stock Up More Than 100% in 6 Months: What's in Store for 2026?
- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Receives Average Rating of “Buy” from Analysts
- MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference
- 5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026
- MindMed Announces New Employee Inducement Grant
Your note
Sign in to keep a note on MNMD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARROW ROBERT B | Chief Executive Officer | Sale | Dec 25, 2025 | 778,477 |
| GRYSKA DAVID W | Director | Purchase | Dec 4, 2024 | 19,851 |
| HALPERIN WERNLI MIRIAM | Officer | Conversion of Exercise of derivative security | Aug 20, 2024 | 202,405 |
| KARLIN DANIEL ROLLINGS | Officer | Sale | Dec 25, 2025 | 425,025 |
| LIAO CARRIE FENG JU | Officer | Sale | Mar 24, 2025 | 144,923 |
| SULLIVAN MARK R | Officer | Sale | Dec 25, 2025 | 282,576 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BlackRock Inc | 7.63% | 5,802,139 | 0 | Jun 29, 2025 |
| COMMODORE CAPITAL LP | 6.57% | 5,000,000 | 0 | Jun 29, 2025 |
| Blackstone Inc | 4.71% | 3,587,479 | 0 | Jun 29, 2025 |
| Marshall Wace Asset Management Ltd | 4.50% | 3,421,224 | 0 | Jun 29, 2025 |
| Driehaus Capital Management LLC | 4.06% | 3,092,658 | 0 | Jun 29, 2025 |
| Deep Track Capital, LP | 3.29% | 2,500,000 | 0 | Jun 29, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Russell 2000 ETF | 2.41% | 1,831,964 | 0 | Aug 30, 2025 |
| Fidelity Small Cap Index | 1.00% | 757,609 | 0 | Jun 29, 2025 |
| Vanguard Institutional Extnd Mkt Idx Tr | 0.97% | 734,703 | 0 | Jul 30, 2025 |
| Heptagon Driehaus US Micro Cap Eq C$ Acc | 0.92% | 702,748 | 0 | Jul 30, 2025 |
| iShares Russell 2000 Value ETF | 0.61% | 461,226 | 0 | Aug 30, 2025 |
| Fidelity Extended Market Index | 0.49% | 369,527 | 0 | Jul 30, 2025 |